Watch our latest video as Philip Boehme discusses decentralized manufacturing as described in an article from the Journal of Pharmaceutical Sciences and how decentralized production in continuous biomanufacturing facilities deploying single-use technologies are increasing supply chain resilience, driving dynamic product allocation based on market demand and reducing environmental footprints. Read the full article here- https://hubs.ly/Q02PJCNb0 Contact Us at [email protected] More information- https://hubs.ly/Q02PJGDH0 #Decentralizedbiomanufacturing #JustEvotecBiologics #ContinuousBiomanufacturing
Just - Evotec Biologics
Biotechnology Research
Seattle, WA 13,739 followers
Designing and applying innovative technologies to dramatically expand global access to biotherapeutics.
Über uns
Just – Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just – Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com
- Website
-
https://www.evotec.com/en/services/just-evotec-biologics
External link for Just - Evotec Biologics
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 501-1,000 employees
- Hauptsitz
- Seattle, WA
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2014
- Spezialitäten
- Molecule Design/ Engineering, Process Development, Analytical Development, Formulation & Drug Product Development, Clinical Manufacturing, Discovery Services, Preclinical Manufacturing, cGMP Manufacturing, CDMO Services, Biosimilars, Antibody therapeutics, biologics manufacturing, cell line development, Biotherapeutics, Biologics, and Biomanufacturing
Standorte
-
Primäre
401 Terry Avenue North
Seattle, WA 98109, US
-
22857 NE Marketplace Drive
Redmond, WA 98053, US
-
195 route d‘Espagne
Toulouse, FR
Employees at Just - Evotec Biologics
Aktualisierungen
-
Congratulations to researchers from the Department of Chemical Engineering, Indian Institute of Technology, Delhi, India and the Welcome Trust, London, UK on their publication “Global outlook on affordability of biotherapeutic drugs”. Here are our key takeaways: 1. High molecular weight biologics (many of them #antibodies) are unaffordable in a large proportion of countries studied. 2. When biosimilars enter the market the price decreases and patient access increases. 3. The price of biotherapeutics is particularly high in the USA. 4. The gap in affordability between the highest and lowest income countries is expected to increase. 5. The harmonization of regulatory pathways needs strengthening in LMICs. Download the article: https://hubs.ly/Q02PHDmF0 Just - Evotec Biologics’ mission is to design and apply innovative technologies to dramatically expand global access to biotherapeutics.
-
Elevate your mAb development strategy at the 9th Bioproduction Congress. We'll be showcasing our J. MD & J.CHO services - designed to streamline your process & maximize results. Hear from our experts: Francois Coutard & Christophe Martin will share insights on early mAb Sequence Optimization. Key presentation: Early mAb Sequence Optimization: The key to developability & cost savings September 25th | 17:40 Schedule a meeting at the Congress: https://hubs.ly/Q02M__Mp0 or reach out to us via [email protected] #Bioproduction #mAbs
-
The Future of Commercial Biologics Production: Continuous Manufacturing Continuous manufacturing is changing the way the industry produces biopharmaceutical products. Unlike traditional fed-batch processing, this innovative approach ensures an uninterrupted flow, leading to a steady and consistent output. The key benefits are: - Reduced Process Costs & Lower COGM: Continuous manufacturing significantly cuts down on production expenses, making biologics more affordable. - Scalability & Adaptability: This method easily scales to meet fluctuating demands, ensuring a reliable supply of life-saving therapies. - Minimized Risks: With fewer process and scalability risks, continuous manufacturing offers a more robust and reliable production system. Explore how continuous manufacturing can address the high cost structure of biologics and meet the rising global demand for these essential therapies. Read the blog- https://hubs.ly/Q02NYHKQ0 Contact us: [email protected] #Biologics #ContinuousManufacturing #Pharmaceuticals #Innovation #Healthcare #LifeSciences
-
The biomanufacturing landscape is changing. Are you ready? Continuous manufacturing is gaining momentum, offering significant advantages over traditional Very Large-Scale (VLS) approaches. Don't get left behind. Read our blog to understand the six key drivers of this shift. Read now: https://hubs.ly/Q02Nn3TN0 To learn more about continuous manufacturing at Just – Evotec Biologics, visit: https://hubs.ly/Q02Nn38X0 or contact us via: [email protected] #Biomanufacturing #ContinuousManufacturing #Biopharma
-
Evotec and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery. In partnership with Evotec’s screening platforms and capabilities, X-Chem is providing access to its DEL technology, including DELflex, a traditional experimental DEL solution, and HITMiner, a machine learning solution, leveraging high quality experimental DEL data to deliver optimal drug intervention starting points for innovative biological targets. To learn more, read the full press release here- https://hubs.ly/Q02NNq4Z0 #ResearchNeverStops #TogetherForMedicinesThatMatter
-
Once a feasibility study has shown that your fed-batch process would benefit from being converted to a #continuousbiomanufacturing platform, what are the next steps? Just - Evotec Biologics offers Commercial Process Development services that establish your product on a 25-day fully end-to-end continuous biomanufacturing platform and assess robustness. To learn more visit our website: https://hubs.ly/Q02Nz1cv0 Or contact us: [email protected]
-
It's time to revolutionize your drug development process. Join Evotec and Just - Evotec Biologics at CPhI Milan and discover how we're pushing the boundaries of what's possible. Explore our cutting-edge solutions: - API and drug product capabilities to accelerate your path to market - Innovative development and manufacturing services for antibody and antibody-related therapeutics - Integrated continuous manufacturing platforms for unparalleled efficiency and flexibility Curious to see it all in action? Schedule a meeting with our experts to discuss your specific needs, or book a site visit to our Verona facility and witness innovation firsthand. Find all the details you need here: https://hubs.ly/Q02Nk4M40 #CPHI #DrugDevelopment #Biologics
-
Understand the Sustainability Benefits of #ContinuousBiomanufacturing The NIIMBL Process Intensification Sustainability workstream is paving the way for sustainable, carbon-neutral bioprocessing of mAbs by 2030. By adopting intensified, continuous manufacturing with single-use technologies, they’re taking significant steps towards a greener future. As a first step, they have assessed the process mass intensity (PMI), energy usage, and CO2 equivalent emissions of both fed batch and continuous manufacturing formats. Download Poster- https://hubs.ly/Q02N8xxF0 To learn more about continuous manufacturing at Just – Evotec Biologics, visit-https://hubs.ly/Q02N8vB50 Contact Us: [email protected]
-
Interested in learning more about bottlenecks in the #biologics market? Welcome to our mini-series covering this topic. In this first article we discuss limitations in #biomanufacturing and look at key challenges and how they can be overcome. https://hubs.ly/Q02MRQfc0 #biotherapeutics #ResearchNeverStops